A complete application in a minute
Tailored resume and cover letter, ready to send.
Menarini Stemline is seeking a Director of Clinical & Value Evidence Liaison to serve as a scientific partner to payer and population health decision-makers across the US. The role emphasizes HEOR/RWE, data-driven value propositions, and cross-functional collaboration with Market Access and Medical Affairs.
You will lead regional scientific exchanges, contribute topre-launch and post-launch activities, and build external partnerships with key stakeholders.
Company:
0750 Stemline Therapeutics Inc
Contract Type:
Permanent
About Menarini Group - Menarini is a leading international biopharmaceutical company committed to advancing health through innovation, research, and quality. For more than 135 years, we have worked to improve patients’ lives across a broad range of therapeutic areas through our dedication to science, integrity, and care for people. With a strong foundation in scientific excellence and a purpose-driven culture, Menarini offers diverse career opportunities for professionals eager to make a meaningful impact on global health.
The Director, Clinical & Value Evidence Liaison is a field-facing role within Medical Affairs whose main objective is to be a trusted scientific partner to key external payer and other population health decision-maker (PHDM) experts by conducting timely, appropriate scientific exchanges to enhance the understanding of the scientific and clinical value of Menarini Stemline products. In addition, the Director, Clinical & Value Evidence Liaison will develop opportunities to partner with PHDMs in a collaborative research project capacity, meeting shared goals and objectives. External customers include Managed Care Organizations (MCOs), large physician groups, health systems, Group Purchasing Organizations (GPOs), Pharmacy Benefit Managements (PBMs), Governmental Agencies (VA/DoD System), Medicare, Integrated Delivery Networks (IDNs) and Oncology Clinical Pathway Developers in the assigned region/geography.
The Director, Clinical & Value Evidence Liaison is responsible for supporting and partnering with key internal business partners, primarily colleagues in Market Access that have field responsibilities. This individual will contribute to business planning and internal business partner teams by providing strategic clinical and health outcomes input along with customer insights. They will maintain a high level of key account management and build external relationships with recognized experts in managed markets/healthcare systems.
This individual has a proven leadership track record with exceptional communication, collaboration and prioritizing skills. They will support pre- and post-launch activities. As part of the Medical Affairs team, this position contributes to and supports the company’s efforts in communicating the high value of Menarini Stemline products to address unmet medical needs.They also support evidence generation through real-world evidence (RWE) initiatives.
Base Salary Range of $240,000-272,000. Menarini Stemline offers generous compensation and benefits packages, including, Fidelity 401(k) (with company match), PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.
Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.
240000
Menarini Stemline offers generous compensation and benefits packages, including Fidelity 401(k) (with company match), Healthcare insurance, Company-paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.
Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.
Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.
Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group’s 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.
Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123‑targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).
Menarini’s vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.
It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.
For more details on how we handle your data, please refer to our Privacy Policy.